



**Catabasis Pharmaceuticals to Report Second Quarter 2020 Financial Results on Monday, August 10<sup>th</sup>**

**BOSTON, Mass., July 27, 2020** – [Catabasis Pharmaceuticals, Inc.](#) (NASDAQ:CATB), a clinical-stage biopharmaceutical company, will report second quarter 2020 financial results after the Nasdaq Global Market close on Monday, August 10, 2020.

**About Catabasis**

At Catabasis Pharmaceuticals, our mission is to bring hope and life-changing therapies to patients and their families. Our lead program is edasalonexent, an NF-kB inhibitor in Phase 3 development for the treatment of Duchenne muscular dystrophy. For more information on edasalonexent and our Phase 3 PolarisDMD trial, please visit [www.catabasis.com](http://www.catabasis.com).

###

Investor and Media Contact

Andrea Matthews

Catabasis Pharmaceuticals, Inc.

T: (617) 349-1971

[amatthews@catabasis.com](mailto:amatthews@catabasis.com)